Samuel Ojosnegros
IBEC researchers develop new technology for assisted reproduction that will reduce time to pregnancy
A new technique developed at the Institute for Bioengineering for Catalonia (IBEC) makes it possible to classify the quality of embryos faster and twice as accurately as expert embryologists. The technology, called “METAPHOR”, uses imaging and artificial intelligence to analyse the metabolism of embryos and oocytes. METAPHOR promises to drastically reduce the time and treatment cycles needed to achieve pregnancy through in vitro fertilisation, minimising the emotional and financial burden on patients.
IBEC researchers are part of the European ATTRACT Project to develop a diagnostic device to improve embryo selection for in vitro fertilization procedures
HYLIGHT Project, coordinated by Samuel Ojosnegros from IBEC, was selected by the ATTRACT Phase 2, an initiative of the European Union to boost the transfer of deep technology with great potential to transfer from the laboratories to the society. The project was financed with around 2M euros for 26 months and aims to develop a diagnostic device to select embryos based on their metabolic profiles and increase the success rates of in vitro fertilization techniques.
El IBEC recibe cerca de un millón de euros para estudiar las enfermedades respiratorias graves causadas por virus
El projecto REACT, liderado por el Statens Serum Institut de Dinamarca, cuenta con la participación del Instituto de Bioingeniería de Cataluña (IBEC) que, con un presupuesto cercano al millón de euros de un total de siete, generará organoides epiteliales nasales humanos específicos como plataformas de validación y modelos preclínicos para investigar la interacción huésped-patógeno .
14th IBEC Symposium brings international experts and 300 attendees together
International experts and three hundred registered attendees met in the 14th IBEC Symposium, dedicated to regenerative therapies. Organised by the Institute for Bioengineering of Catalonia (IBEC), speakers presented the latest advances in mini-organs, organs on a chip, 3D bioprinting and tissue engineering, among others.
Entrepreneurs of the future visit IBEC
MBA students visit the Institute for Bioengineering of Catalonia (IBEC) in a conference organized by Barcelona Global.
IBEC and Oxolife start a pioneering study to treat infertility
Oxolife, the biotechnological startup focused on the development of drugs to improve female fertility, and the Bioengineering for Reproductive Health laboratory of the Institute for Bioengineering of Catalonia (IBEC), will combine two pioneering technologies for the study and treatment of infertility.
Oxolife, the biotechnological startup focused on the development of drugs to improve female fertility, and the Bioengineering for Reproductive Health laboratory of the Institute for Bioengineering of Catalonia (IBEC), will combine two pioneering technologies for the study and treatment of infertility. Senior researcher at the Bioengineering in Reproductive Health Research Group
Application Deadline: 15/07/2020
Ref: SR-SO
The Bioengineering in reproductive health group at the Institute for Bioengineering of Catalonia (IBEC) is looking for a Senior Scientist to develop a project in collaboration with the industry.
The project involves investigate the molecular mechanisms affected by specific chemical treatments on endometrial receptivity and on mouse and human embryos in culture. We aim to combine the expertise in microscopy of the lab with embryology tools to understand the morphological and molecular modifications that lead to an increase in endometrial receptivity. An ideal candidate will have experience in the mouse or human embryology field and will know basic tools of molecular biology. The candidate will have a great degree of independence to coordinate the project, competitive salary and funding to outsource several tests (i.e. sequencing, histology etc.).
Our laboratory is a multidisciplinary environment where biologists, biophysicists, clinicians and business developers synergize to create a unique environment shaped by science and entrepreneurship. Due to the high translational component of our research, we have established collaboration contracts with the pharma industry, hospitals and venture capital to bring our technology to the clinics and the market.
In our lab we use bioengineering methods to create 3D environments that support embryonic development outside of the mother uterus. Our systems are accessible to imaging tools which allow us to interrogate the genetics, metabolomics and mechanics of the embryo in a high throughput manner. Using our systems we are capable to (i) improve embryo culture conditions and (ii) diagnose embryos with improved implantation potential.